|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Cash flows from operating activities | ||||
| Net income | ||||
| Adjustments to reconcile net income to net cash provided by (used in) operating activities | ||||
| Depreciation and amortization | ||||
| Impairment loss on real estate | ||||
| Loss (gain) on exchange of Exchangeable Senior Notes | ||||
| Loss (gain) on sale of real estate | ||||
| Other non-cash adjustments | ||||
| Paid-in-kind dividends and interest income on life science investments | ||||
| Stock-based compensation | ||||
| Amortization of discounts on investments | ||||
| Amortization of debt discount and issuance costs | ||||
| Changes in assets and liabilities | ||||
| Other assets, net | ||||
| Accounts payable, accrued expenses and other liabilities | ||||
| Rent received in advance and tenant security deposits | ||||
| Net cash provided by (used in) operating activities | ||||
| Cash flows from investing activities | ||||
| Investments in real estate | ||||
| Investments in life science financial instruments | ||||
| Proceeds from sale of real estate assets | ||||
| Funding of draws for improvements and construction | ||||
| Funding of construction loan and other investments | ||||
| Purchases of short-term investments | ||||
| Maturities of short-term investments | ||||
| Net cash provided by (used in) investing activities | ||||
| Cash flows from financing activities | ||||
| Issuance of common stock, net of issuance costs | ||||
| Repurchase of common stock | ||||
| Issuance of preferred stock, net of issuance costs | ||||
| Principal payment on Exchangeable Senior Notes | ||||
| Draws on revolving credit facilities | ||||
| Repayments on revolving credit facilities | ||||
| Principal payment on debt | ||||
| Payment of deferred financing costs | ||||
| Taxes paid related to net share settlement of equity awards | ||||
| Net cash provided by (used in) financing activities | ||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | ||||
| Cash, cash equivalents and restricted cash, beginning of year | ||||
| Cash, cash equivalents and restricted cash, end of year | ||||
| Supplemental disclosure of cash flow information: | ||||
| Cash paid during the year for interest, net of interest capitalized | ||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||
| Accrual for current-period additions to real estate | ||||
| Deposits applied for acquisitions | ||||
| Accrual for common and preferred stock dividends declared | ||||
| Reclassification from other assets to real estate held for investment | ||||
| Exchange of Exchangeable Senior Notes for common stock | ||||
Loading...
